Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

Inclusion Criteria: * age \>18 years of age * visual acuity 20/100 to CF * duration of vision loss \> 3 months * vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion or diabetic retinopathy * the study eye has the worse visual acuity * no active eye or systemic disease * no history of macular edema or retinal/choroidal neovascularization requiring treatment within 6 months * no significant media opacity * no coagulopathy or other hematologic abnormality * no concurrent immunosuppressive therapy * able to keep follow-up for 6 months Exclusion Criteria: * allergy to fluorescein dye * other concurrent retinal or optic nerve disease affecting vision